Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

Stopped early

Conditions studied: Cancer

In brief

RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who have undergone stem cell transplant for cancer.

Key facts

Study ID

NCT00949052

Run by

Vanderbilt-Ingram Cancer Center

People needed

1000

Starts

2009-01-01

Expected to finish

2018-02-01

Last updated by the study team

2018-08-16

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• CASES are those who:
• Survived at least 100 days post-hematopoietic stem cell transplantation (HSCT).
• Developed an SMN after that time point.
• And received TBI as part of the preparative regimen.
• CONTROLS are randomly selected:
• In a 4:1 ratio to cases from the same cohort of 100 day + survivors of HSCT who received TBI.
• Controls will be matched to the cases by race and primary diagnosis.
• In addition, they must have survived for at least the elapsed time between the case's HSCT and the secondary cancer, without development of an SMN.
• We are matching on primary diagnosis, as genotype or radiation sensitivity may predispose to specific primary cancers, as well as the SMNs.
• We are matching on race, as allele frequencies vary widely across ethnic groups.

You may not qualify if…

• Did not survive at least 100 days post-hematopoietic stem cell transplantation (HSCT).
• Did not develop an SMN after that time point.
• Did not receive TBI as part of the preparative regimen.

Where it is running

• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.